In its latest quarterly report, Intuitive Surgical delivered $2.53 in adjusted EPS, surpassing consensus by $0.26, on revenue of $2.87 billion, up 18.8% year-over-year. System placements increased by 12% to 405 units globally, driving consumables and services revenue growth of 21%. Despite the beat, management guided to mid-single-digit revenue growth and EPS of approximately $10.00 to $10.20 for the full fiscal year, below Street forecasts, citing ongoing hospital budget constraints in select markets.

Alpha Cubed Investments LLC raised its stake by 13.0%, acquiring 10,677 additional shares to hold 92,600 shares valued at $41.4 million at quarter end, making ISRG its 19th largest holding. Valley Wealth Managers increased its position by 52.7% to 4,084 shares, Tandem Investment Advisors added 396 shares for a 4.5% gain, Strategic Advisors lifted its stake by 63.3% to 10,397 shares, AE Wealth Management boosted holdings by 18.9% to 11,556 shares, and LRI Investments grew its position by 24% to 1,997 shares. Institutional ownership stands at 83.6%.

The FDA granted clearance for da Vinci 5 in select advanced cardiac procedures, opening an estimated $1.5 billion incremental addressable market for systems and consumables over the next five years. TD Cowen initiated coverage with a strong-buy, Barclays and HSBC reaffirmed buy ratings with bullish price targets, and Daiwa Capital Markets raised its target from $510 to $550. While some firms trimmed near-term targets, overall analyst conviction remains high, supported by recurring consumable revenue streams and service contracts.

Corporate insiders have disposed of 75,557 shares valued at over $42 million in the past 90 days. Director Gary S. Guthart sold 27,300 shares, EVP Henry L. Charlton offloaded 13,731 shares, SVP Mark Brosius sold 4,500 shares, and EVP Myriam Curet divested 230 shares. This wave of sales, representing over 0.7% of outstanding stock, could temper sentiment despite robust fundamentals.